January 2020 - Novocure

We have revised our Privacy Policy that is in effect as of May 25, 2018. Please click here to access it.

about us

corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.

leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.

corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
our therapy
our pipeline

clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.

novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
patient-forward
news and media

press releases

press kits

media gallery

featured stories
investor relations

press releases

corporate presentation

events

annual reports

sec filings

stock information

corporate governance

faq

email alerts

NASDAQ: current stock price

108.98

1.73

last update 9/17/2020 16:00pm
careers

our locations

current job listings

Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

January 21, 2020

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients with newly diagnosed glioblastoma. The medical services basket includes the entire range of services, medications and devices that the insured public …

Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update

January 13, 2020

Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 2018 Novocure to present at the 38th Annual J.P. Morgan Healthcare Conference at 10:00 a.m. PST on Monday, Jan. 13, 2020 Fourth quarter and full year 2019 financial results to be reported Thursday, Feb. 27, 2020 ST. HELIER, …

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

January 09, 2020

SHANGHAI & ST. HELIER, Jersey–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the first patient has been enrolled in a phase 2 pilot clinical trial evaluating the safety …

about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
our therapy
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
patient-forward
news and media
investor relations
careers
- our locations
- current job listings